Delivery Order SPE2DB25D9320-SPE2DB25FWFBQ
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 1, 2025, by the Defense Logistics Agency (DLA) for JAKAFI 20 mg tablets (60-count units) with a ceiling value of $12,089.78. This firm fixed-price delivery order, which has an ultimate completion date of August 4, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $24,793.16 to DMS Pharmaceutical Group Inc. for 60 tablets of JAKAFI 5 MG on December 1, 2025, with an ultimate completion date of December 2, 2025. This firm fixed-price delivery order was issued without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,115.65 to DMS Pharmaceutical Group Inc. on July 14, 2025, for the supply of JAKAFI 10 mg tablets (60-count units). This firm fixed-price delivery order, which has an ultimate completion date of July 15, 2025, was issued without set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this delivery from its Illinois location....
- The Defense Logistics Agency awarded a $48,462.60 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of JAKAFI 10 mg tablets (60-count packages). The contract, executed on October 31, 2025, with an ultimate completion date of November 3, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. This award was issued under DMS Pharmaceutical Group's single-award...
- The Defense Logistics Agency awarded a delivery order valued at $24,293.60 to DMS Pharmaceutical Group Inc. for the supply of Jakafi 5 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected through a firm fixed-price delivery order with an ultimate completion date of September 10, 2025. This award carries no set-aside designation, indicating the company competed on an unrestricted...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $24,729.64 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 60 tablets of JAKAFI 10 mg. This delivery order was issued without a set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award was issued on December 22, 2025, with an ultimate completion date of December 23,...
- The Defense Logistics Agency issued a firm fixed-price delivery order valued at $12,364.81 to DMS Pharmaceutical Group Inc. for the supply of JAKAFI 10 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded this delivery order on December 30, 2025, with an ultimate completion date of December 31, 2025. The award carried no set-aside designation, demonstrating the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $24,293.60 to DMS Pharmaceutical Group Inc. for the supply of Jakafi 5 mg tablets (60-unit quantity) on August 12, 2025, with an ultimate completion date of August 13, 2025. This firm fixed-price delivery order was issued without a set-aside designation and is being performed at the vendor's location in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, serves as the prime...
- The U.S. government agency Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $11,840.66 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of the pharmaceutical product JAKAFI 10 MG TABLET 60S. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,146.79 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Jakafi 5 mg tablets (60-count units). The contract, awarded on September 9, 2025, with an ultimate completion date of September 10, 2025, represents a firm fixed-price delivery order with no set-aside designation applied. This award falls under DMS Pharmaceutical Group's larger...
- SPE2DB25D9320Indefinite Delivery Contract
- SPE2DB25D9320-SPE2DB25FWFBQDelivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,231.30 to DMS Pharmaceutical Group Inc. for JAKAFI 10 mg tablets (60-count units) on July 14, 2025, with an ultimate completion date of July 15, 2025. This delivery order was issued without a set-aside designation and represents a direct purchase under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA, valued at $499.9 million through November 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, serves as a critical supplier to the Defense Logistics Agency's pharmaceutical distribution network supporting military healthcare facilities. The award exemplifies DLA's procurement approach for routine pharmaceutical supply needs, leveraging pre-established IDC agreements to streamline the acquisition of branded medications and specialty pharmaceuticals for Department of Defense medical supply chains. JAKAFI (ruxolitinib) is an FDA-approved pharmaceutical used in treating certain blood disorders and conditions, reflecting the breadth of specialty medications within DMS Pharmaceutical Group's product portfolio. The company's established relationship with DLA and demonstrated capacity to supply pharmaceutical products across multiple categories positions it as a reliable vendor for federal health system requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $24.2k | 7/14/25 |